{"id":53277,"date":"2026-01-08T00:52:40","date_gmt":"2026-01-07T16:52:40","guid":{"rendered":"https:\/\/flcube.com\/?p=53277"},"modified":"2026-01-08T00:52:42","modified_gmt":"2026-01-07T16:52:42","slug":"ikarovec-and-vectorbuilder-sign-1-billion-aav-capsid-deal-for-amd-gene-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53277","title":{"rendered":"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy"},"content":{"rendered":"\n<p><strong>Ikarovec<\/strong>, a UK\u2011based gene therapy company, and <strong>VectorBuilder<\/strong>, a leader in gene delivery, announced a <strong>global exclusive option agreement<\/strong> for VectorBuilder\u2019s <strong>next\u2011generation AAV capsid technology<\/strong> to develop <strong>IKAR\u2011003<\/strong>, Ikarovec\u2019s gene therapy candidate for <strong>intermediate age\u2011related macular degeneration (iAMD)<\/strong>. The partnership, valued at over <strong>$1 billion<\/strong>, aims to accelerate development of a single\u2011injection outpatient treatment that could transform the iAMD landscape.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-amp-technology-overview\">Transaction &amp; Technology Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Ikarovec (UK), VectorBuilder (gene delivery leader)<\/td><\/tr><tr><td><strong>Agreement<\/strong><\/td><td>Global exclusive option agreement for AAV capsid technology<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>IKAR\u2011003 (AAV\u2011mediated gene therapy for iAMD)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Next\u2011generation AAV capsid for intravitreal injection<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Single\u2011injection, outpatient setting (no hospital surgery)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Neuroprotection + complement pathway regulation<\/td><\/tr><tr><td><strong>Total Value<\/strong><\/td><td>Expected to exceed <strong>$1 billion<\/strong><\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Option \u2192 strategic partnership post\u2011technical evaluation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-ikar-003\">Product Profile: IKAR\u2011003<\/h2>\n\n\n\n<p><strong>Therapeutic Approach<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Mechanism<\/strong>: Simultaneously introduces <strong>neuroprotective genes<\/strong> and <strong>complement pathway regulators<\/strong> to preserve visual function and halt disease progression<\/li>\n\n\n\n<li><strong>Delivery<\/strong>: VectorBuilder\u2019s proprietary AAV capsid enables <strong>minimally invasive intravitreal injection<\/strong>, overcoming surgical barriers of subretinal delivery<\/li>\n\n\n\n<li><strong>Dosing<\/strong>: <strong>Single injection<\/strong> vs. chronic anti\u2011VEGF therapy for wet AMD<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Significance<\/strong>: Addresses <strong>intermediate AMD (iAMD)<\/strong>, a <strong>\u00a515\u202fbillion<\/strong> (US$2.1\u202fbillion) global market with <strong>no approved disease\u2011modifying therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>iAMD Epidemiology<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Prevalence<\/strong>: <strong>200\u202fmillion<\/strong> people aged 50+ have early\/intermediate AMD<\/li>\n\n\n\n<li><strong>Progression Risk<\/strong>: <strong>15\u201120%<\/strong> of iAMD patients progress to wet AMD annually<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: <strong>Zero approved therapies<\/strong> for iAMD; patients rely on <strong>monitoring and supplements<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China iAMD Market<\/strong>: <strong>\u00a53.5\u202fbillion<\/strong> (2025), growing at <strong>18% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Global Market<\/strong>: <strong>$8\u202fbillion<\/strong> opportunity by 2030<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>$50,000\u201180,000 per injection<\/strong> (comparable to gene therapies)<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Landscape<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NGM Biopharmaceuticals<\/strong>: C3 inhibitor in Phase\u202fII (subretinal injection)<\/li>\n\n\n\n<li><strong>Gyroscope Therapeutics<\/strong>: Gene therapy in Phase\u202fII (surgical delivery)<\/li>\n\n\n\n<li><strong>Ikarovec\u2011VectorBuilder<\/strong>: <strong>First outpatient gene therapy<\/strong> for iAMD<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For Ikarovec<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Access<\/strong>: VectorBuilder\u2019s AAV capsid solves <strong>delivery challenge<\/strong>, enabling <strong>scalable, non\u2011surgical treatment<\/strong><\/li>\n\n\n\n<li><strong>Clinical Speed<\/strong>: Accelerates <strong>Phase\u202fI initiation by 12\u201118 months<\/strong> vs. developing capsid in\u2011house<\/li>\n\n\n\n<li><strong>Commercial Differentiation<\/strong>: <strong>Outpatient administration<\/strong> expands addressable patient population by <strong>3\u20115x<\/strong> vs. surgical approaches<\/li>\n<\/ul>\n\n\n\n<p><strong>For VectorBuilder<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Partnership with <strong>clinical\u2011stage gene therapy company<\/strong> demonstrates capsid utility in high\u2011value indication<\/li>\n\n\n\n<li><strong>Financial Upside<\/strong>: <strong>$1 billion+ deal<\/strong> includes <strong>milestone payments<\/strong> and <strong>royalties<\/strong> on future sales<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Capsid technology applicable to <strong>retinal, CNS, and systemic diseases<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pathway\">Development Pathway<\/h2>\n\n\n\n<p><strong>Technical Evaluation Phase<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Timeline<\/strong>: <strong>6\u20119 months<\/strong> to validate capsid performance in <strong>non\u2011human primate models<\/strong><\/li>\n\n\n\n<li><strong>Success Criteria<\/strong>: <strong>Transduction efficiency >80%<\/strong>, <strong>safety profile clean<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Partnership Phase<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Responsibilities<\/strong>: Ikarovec leads <strong>clinical development, regulatory, and commercialization<\/strong>; VectorBuilder provides <strong>technical support and manufacturing<\/strong><\/li>\n\n\n\n<li><strong>Milestones<\/strong>: Tied to <strong>IND filing (2026)<\/strong>, <strong>Phase\u202fIII initiation (2028)<\/strong>, and <strong>NDA approval (2030)<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Global Reach<\/strong>: Partnership covers <strong>all markets<\/strong>, with Ikarovec focusing on <strong>U.S.\/EU<\/strong> and exploring <strong>China partnership<\/strong> via VectorBuilder\u2019s network.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<p><strong>Structure<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront Option Fee<\/strong>: <strong>USD\u202f20\u201130\u202fmillion<\/strong> (estimated)<\/li>\n\n\n\n<li><strong>Milestone Payments<\/strong>: <strong>USD\u202f300\u2011500\u202fmillion<\/strong> tied to clinical and regulatory achievements<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: <strong>Mid\u2011single to low\u2011double digit<\/strong> on net sales<\/li>\n\n\n\n<li><strong>Equity<\/strong>: VectorBuilder may receive <strong>minority stake<\/strong> in Ikarovec upon NewCo formation<\/li>\n<\/ul>\n\n\n\n<p><strong>Total Value<\/strong>: Exceeds <strong>USD\u202f1 billion<\/strong> across <strong>development and commercial phases<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the partnership\u2019s technical success, clinical development timelines, and market opportunity for IKAR\u2011003. Actual results may differ materially due to preclinical data outcomes, regulatory acceptance of intravitreal gene therapy, competitive responses, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ikarovec, a UK\u2011based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4537,1405],"class_list":["post-53277","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ikarovec","tag-vectorbuilder"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ikarovec, a UK\u2011based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a global exclusive option agreement for VectorBuilder\u2019s next\u2011generation AAV capsid technology to develop IKAR\u2011003, Ikarovec\u2019s gene therapy candidate for intermediate age\u2011related macular degeneration (iAMD). The partnership, valued at over $1 billion, aims to accelerate development of a single\u2011injection outpatient treatment that could transform the iAMD landscape.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53277\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy\" \/>\n<meta property=\"og:description\" content=\"Ikarovec, a UK\u2011based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a global exclusive option agreement for VectorBuilder\u2019s next\u2011generation AAV capsid technology to develop IKAR\u2011003, Ikarovec\u2019s gene therapy candidate for intermediate age\u2011related macular degeneration (iAMD). The partnership, valued at over $1 billion, aims to accelerate development of a single\u2011injection outpatient treatment that could transform the iAMD landscape.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53277\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T16:52:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T16:52:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53277#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53277\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy\",\"datePublished\":\"2026-01-07T16:52:40+00:00\",\"dateModified\":\"2026-01-07T16:52:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53277\"},\"wordCount\":553,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ikarovec\",\"VectorBuilder\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53277#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53277\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53277\",\"name\":\"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T16:52:40+00:00\",\"dateModified\":\"2026-01-07T16:52:42+00:00\",\"description\":\"Ikarovec, a UK\u2011based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a global exclusive option agreement for VectorBuilder\u2019s next\u2011generation AAV capsid technology to develop IKAR\u2011003, Ikarovec\u2019s gene therapy candidate for intermediate age\u2011related macular degeneration (iAMD). The partnership, valued at over $1 billion, aims to accelerate development of a single\u2011injection outpatient treatment that could transform the iAMD landscape.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53277#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53277\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53277#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Ikarovec, a UK\u2011based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a global exclusive option agreement for VectorBuilder\u2019s next\u2011generation AAV capsid technology to develop IKAR\u2011003, Ikarovec\u2019s gene therapy candidate for intermediate age\u2011related macular degeneration (iAMD). The partnership, valued at over $1 billion, aims to accelerate development of a single\u2011injection outpatient treatment that could transform the iAMD landscape.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53277","og_locale":"en_US","og_type":"article","og_title":"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy","og_description":"Ikarovec, a UK\u2011based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a global exclusive option agreement for VectorBuilder\u2019s next\u2011generation AAV capsid technology to develop IKAR\u2011003, Ikarovec\u2019s gene therapy candidate for intermediate age\u2011related macular degeneration (iAMD). The partnership, valued at over $1 billion, aims to accelerate development of a single\u2011injection outpatient treatment that could transform the iAMD landscape.","og_url":"https:\/\/flcube.com\/?p=53277","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T16:52:40+00:00","article_modified_time":"2026-01-07T16:52:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53277#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53277"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy","datePublished":"2026-01-07T16:52:40+00:00","dateModified":"2026-01-07T16:52:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53277"},"wordCount":553,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ikarovec","VectorBuilder"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53277#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53277","url":"https:\/\/flcube.com\/?p=53277","name":"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T16:52:40+00:00","dateModified":"2026-01-07T16:52:42+00:00","description":"Ikarovec, a UK\u2011based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a global exclusive option agreement for VectorBuilder\u2019s next\u2011generation AAV capsid technology to develop IKAR\u2011003, Ikarovec\u2019s gene therapy candidate for intermediate age\u2011related macular degeneration (iAMD). The partnership, valued at over $1 billion, aims to accelerate development of a single\u2011injection outpatient treatment that could transform the iAMD landscape.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53277#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53277"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53277#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53277"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53277\/revisions"}],"predecessor-version":[{"id":53280,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53277\/revisions\/53280"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}